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Bryostatin-1 is a macrocyclic lactone whose main mechanism of action is protein kinase C modulation. We investigated its activity as a
weekly 24-h infusion in recurrent ovarian carcinoma. In all, 17 patients were recruited and 11 had chemotherapy-resistant disease as
defined by disease progression within 4 months of last cytotoxic therapy. All were evaluable for toxicity and 14 for response. There
were no disease responses and the main toxicity was myalgia.
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Although advanced epithelial ovarian cancer is sensitive to
platinum-containing chemotherapy at first presentation, the
majority of patients experience disease relapse and their manage-
ment at this stage is often difficult. While rechallenge with
platinum is appropriate for patients with at least a 6-month
disease-free interval (Markman et al, 1991), those who progress
sooner require treatment with newer agents. The response rates to
these, however, are disappointing and therefore a clear need exists
for the development of novel approaches to the management of
recurrent ovarian carcinoma.
Bryostatin-1 is a naturally occurring macrocyclic lactone with
antineoplastic activity derived from the marine bryozoan, Bugula
neritina (Pettit et al, 1982). In vitro evidence indicates that its main
mechanism of action is the modulation of protein kinase C activity.
How this is antineoplastic is less clear, but may involve apoptosis
induction or immunomodulatory effects (Clamp and Jayson, 2002).
During Phase I evaluation of bryostatin-1, myalgia was shown to
be the main dose-limiting toxicity (Philip et al, 1993; Prendiville
et al, 1993; Varterasian et al, 1998), although the mechanism for this
is not fully understood. A maximum tolerated dose of
25mgm
2week
1 was identified when a weekly 24-h infusion was
used (Jayson et al, 1995). Of note, one partial and one minor
response occurred in two patients with relapsed ovarian cancer in
the trial and so we undertook a Phase II study with this regimen to
evaluate further the efficacy of bryostatin-1 in this group of patients.
MATERIALS AND METHODS
Trial design
This study was a multicentre open label nonrandomised Phase II
trial. The predefined endpoints were response rate and progres-
sion-free interval. To ensure a low probability (Po0.05) of
erroneously rejecting a treatment that is active in 20% of patients,
a minimum of 14 subjects were planned to be treated (Gehan,
1961).
The study was approved by the Cancer Research Campaign
Phase I/II Committee and Central Independent Review Board
(CIRB), the National Cancer Institute and Local Regional Ethics
Committees. Written informed consent was obtained from all
patients.
Patients
Patients eligible for inclusion were at least 18 years old, with
histologically proven epithelial ovarian cancer that had progressed
during or after at least one platinum-containing chemotherapy
regimen. The progression-free interval following last chemother-
apy treatment was not a defined selection criterion. All patients
had a life expectancy of X12 weeks and a WHO performance
status of 0–2. They had radiologically measurable disease X2cm
in two dimensions.
Adequate biochemical and haematological functions were
documented within 1 week of trial entry. Patients were excluded
if they had received more than two prior multidrug regimens for
ovarian cancer and other standard Phase II exclusion criteria
applied. Systemic steroid administration was contraindicated while
patients were receiving bryostatin-1.
Formulation, dose and administration
Bryostatin-1 (US National Cancer Institute, Arizona State Uni-
versity, USA) was stored at 41C in flint vials containing 0.1mg of
lyophilised bryostatin-1. Prior to administration, it was dissolved
in 1ml of PET (60% polyethylene glycol, 30% ethanol, 10% Tween
80) diluent and then diluted with 9ml of 0.9% sodium chloride.
The prescribed volume was then drawn up into a polypropylene Received 23 May 2003; revised 17 July 2003; accepted 24 July 2003
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lsyringe and co-infused intravenously over 24 h with 2l of 0.9%
sodium chloride. Bryostatin-1 was administered weekly at a dose
of 25mgm
2 for a planned eight doses.
In the presence of Grade 3 or 4 myalgia and/or headache,
treatment was delayed for 1 week. If Grade 3 toxicity persisted, the
patient was withdrawn from the trial. If myalgia/headache had
improved to Grade 2 or better, treatment was recommenced at a
25% dose reduction (19mgm
2). If XGrade 3 toxicity recurred,
treatment was discontinued.
If any other Grade 3/4 toxicity (or Grade 1 thrombocytopenia)
occurred, treatment was delayed for 1 week and was then restarted
at 19mgm
2 if recovery had occurred to Grade p1 (except for
thrombocytopenia (Grade 0) and neutropenia (Grade 2)). Recur-
rent toxicity led to treatment withdrawal. If Grade X2 phlebitis
occurred, treatment was delayed for 1 week and then recom-
menced at 25mgm
2. If phlebitis recurred, a 25% dose reduction
was instituted.
Monitoring of toxicity and response
Patients were reviewed by a physician weekly, prior to the
administration of bryostatin-1. Included in this review were the
patient’s WHO performance status and the documentation of any
new symptoms and adverse events according to the NCI-CTC
criteria (version 2.0). A full blood count and serum biochemistry
were performed weekly.
Evaluable and measurable disease sites were assessed after 8
weeks of treatment by the same imaging modality employed prior
to study entry. Serum CA-125 levels were determined weekly.
Patients with progressive disease were withdrawn from the study.
Patients with clear clinical progression were deemed evaluable for
response, provided that they had received at least four infusions of
bryostatin-1. Those patients who had not received four infusions
were replaced.
RESULTS
Patient demographics
In all, 17 patients (median age 60 years, range 43–71) were
recruited. All patients had undergone surgery and platinum-based
chemotherapy after diagnosis. A total of 11 of 16 evaluable patients
had responded to first-line therapy, while two had progressive
disease. 13 patients subsequently received second-line cytotoxics
prior to trial entry. At recruitment all patients had documented
disease progression, 11 had chemotherapy-resistant and nine had
platinum-resistant disease as defined by progressive disease on
treatment or disease relapse within 4 months of discontinuing
therapy. Nine patients had WHO performance status 0, 6 PS1 and 2
PS2 at entry.
Bryostatin-1 administration and response
In total, 95 doses of bryostatin-1 were given to 17 patients with a
median of six doses each (range 2–9). Four were administered at
19mgm
2 due to toxicity. Eight dose delays of 1 week or more
occurred in eight patients. Two were due to toxicity (one myalgia,
one lethargy), three due to concurrent medical problems, one at
patient request due to Grade 2 myalgia and two due to
administrative constraints.
Three patients were considered nonevaluable due to marked
clinical deterioration prior to completing 4 weeks of bryostatin-1
therapy. In all three cases, this was due to rapidly progressive
disease. In all, 14 patients were evaluable. No radiological or CA-
125 responses were noted on therapy. Six patients had early disease
progression as defined by clear clinical and/or radiological
evidence of progression prior to the planned assessment after
eight doses of bryostatin-1. Four patients had progressive disease
and four patients showed disease stabilisation after eight doses. In
all patients with stable disease, treatment was discontinued at
the patients’ request due to the deteriorating quality of life
associated with weekly hospital attendances and the side effects of
bryostatin-1. Two of these patients commenced other cytotoxic
treatment immediately on withdrawal. In addition, one patient
showed disease stabilisation off antineoplastic treatment for 12
months. In the last patient with stable disease, a 94% fall in serum
CA-125 was documented 13 weeks after discontinuing bryostatin-1
and disease regression was confirmed radiologically.
Toxicity
Toxicities attributed to bryostatin-1 are summarised in Table 1.
Eight patients experienced Grade II or III myalgia. This usually
became evident after the second bryostatin-1 infusion and its
intensity and duration increased as the treatment continued. Three
patients who experienced Grade 3 myalgia withdrew from the trial
at their own request. One patient was withdrawn due to Grade 3
lethargy. Notably, the performance status of 13 patients deterio-
rated during therapy.
DISCUSSION
Efficacy
Although activity in epithelial ovarian cancer was documented in a
Phase I study of bryostatin-1 administered as a weekly 24-h
infusion (Jayson et al, 1995), no disease responses were seen in this
Phase II study. This is in keeping with the disappointing results
observed in single-agent Phase II studies performed in other
disease groups using a variety of administration regimens
(summarised in Clamp and Jayson, 2002).
It should be noted, however, that although treatment-
free interval was not a selection criterion for trial entry, the
patient population treated in this study primarily had chemother-
apy-resistant disease. This group is known to have response
rates of 0–27% to novel agents tested in the Phase II setting
(Latorre et al, 2002). Using the statistical principles applied
Table 1 Toxicity probably/definitely attributable to bryostatin-1
(25mgm
2)
NCI-CTC v2.0-grading
Toxicity 2 3 4
Myalgia 4 4 —
Fatigue 1 2 —
Vomiting — 1 —
Lymphocytopenia 6 — —
Dermatology-other 2 — —
Haemoglobin 2 — —
Phlebitis 2 — —
Anorexia 2 — —
Constipation 2 — —
Nausea 1 — —
Diarrhoea 1 — —
Muscle weakness 1 — —
Ocular-other 1 — —
Elevated g-GT 1 — —
Arthralgia 1 — —
Headache 1 — —
Injection site reaction 1 — —
Stomatitis 1 — —
Number of patients with Grade 2 toxicities and above are listed. Only the worst
grade of toxicity noted in each patient is included.
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level and so cannot discount equivalent activity with some
cytotoxic agents in clinical usage.
The demonstration of prolonged stable disease in one patient is
consistent with previous reports with bryostatin-1, particularly in
hypernephroma (Pagliaro et al, 2000), although these patients
continued on therapy until progression. The observation of
delayed disease regression in one patient is intriguing, but difficult
to attribute to bryostatin-1 as initial evidence of response was only
noted 3 months after therapy was discontinued.
Toxicity
Bryostatin-1 caused significant myalgia, with 48% of patients
experiencing at least Grade 2 myalgia on treatment. The short
duration of therapy, the rapid onset of myalgia and its increasing
duration and intensity with cumulative doses all indicate that this
side effect is likely to be a significant impediment to the further
clinical development of this agent. This is further reinforced by the
fact that three of the four patients in this study experiencing Grade
3 myalgia withdrew from treatment at their own request despite
formal documentation of stable disease.
Combination regimens
Given its unique side effect profile, it may be that the future
clinical niche for bryostatin-1 in ovarian cancer will be as part of
combination regimens with conventional cytotoxic agents. Indeed,
preclinical data demonstrate synergy with both cisplatin and
paclitaxel (Basu and Lazo, 1992; Koutcher et al, 2000) and the
safety of cisplatin/bryostatin-1 combinations has already been
demonstrated (Rosenthal et al, 1999). It is particularly intriguing
that encouraging Phase II activity with the combination of
cisplatin and tamoxifen has been reported (Benedetti Panici et al,
2001), as one of tamoxifen’s possible mechanisms of action is the
modulation of PKC activity, suggesting that it could mimic
bryostatin-1 (Schwartz et al, 2002). The combination of bryosta-
tin-1 and paclitaxel, however, may be hampered by severe myalgias
as reported in one study in oesophageal carcinoma (Kortmansky
et al, 2002).
In summary, the results of this trial indicate that bryostatin-1
administered alone at a dose of 25mgm
2 as a weekly 24-h
infusion has no role in the management of relapsed chemotherapy-
resistant epithelial ovarian cancer. Its future utility will depend on
the successful evaluation of combination regimens with other
cytotoxic agents with which it has no overlapping toxicities.
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